183 related articles for article (PubMed ID: 38240781)
21. Maspin enhances cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and correlates with prognosis of muscle-invasive bladder cancer patients receiving cisplatin based neoadjuvant chemotherapy.
Chen J; Wang L; Tang Y; Gong G; Liu L; Chen M; Chen Z; Cui Y; Li C; Cheng X; Qi L; Zu X
J Exp Clin Cancer Res; 2016 Jan; 35():2. PubMed ID: 26733306
[TBL] [Abstract][Full Text] [Related]
22. Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer.
Lamoureux F; Thomas C; Yin MJ; Fazli L; Zoubeidi A; Gleave ME
Eur Urol; 2014 Jul; 66(1):145-55. PubMed ID: 24411988
[TBL] [Abstract][Full Text] [Related]
23. Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses.
Konstantakou EG; Voutsinas GE; Karkoulis PK; Aravantinos G; Margaritis LH; Stravopodis DJ
Int J Oncol; 2009 Aug; 35(2):401-16. PubMed ID: 19578756
[TBL] [Abstract][Full Text] [Related]
24. BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance.
Zhang H; Neely L; Lundgren K; Yang YC; Lough R; Timple N; Burrows F
Int J Cancer; 2010 Mar; 126(5):1226-34. PubMed ID: 19676042
[TBL] [Abstract][Full Text] [Related]
25. Induction of G1 cell cycle arrest and apoptosis by berberine in bladder cancer cells.
Yan K; Zhang C; Feng J; Hou L; Yan L; Zhou Z; Liu Z; Liu C; Fan Y; Zheng B; Xu Z
Eur J Pharmacol; 2011 Jul; 661(1-3):1-7. PubMed ID: 21545798
[TBL] [Abstract][Full Text] [Related]
26. Effects of multi and selective targeted tyrosine kinase inhibitors on function and signaling of different bladder cancer cells.
Hänze J; Kessel F; Di Fazio P; Hofmann R; Hegele A
Biomed Pharmacother; 2018 Oct; 106():316-325. PubMed ID: 29966976
[TBL] [Abstract][Full Text] [Related]
27. BIIB021: A novel inhibitor to heat shock protein 90-addicted oncology.
Yan L; Zhang W; Zhang B; Xuan C; Wang D
Tumour Biol; 2017 Apr; 39(4):1010428317698355. PubMed ID: 28443462
[TBL] [Abstract][Full Text] [Related]
28. Sunitinib can enhance BCG mediated cytotoxicity to transitional cell carcinoma through apoptosis pathway.
Ping SY; Wu CL; Yu DS
Urol Oncol; 2012 Sep; 30(5):652-9. PubMed ID: 20884251
[TBL] [Abstract][Full Text] [Related]
29. Structural Basis for Design of New Purine-Based Inhibitors Targeting the Hydrophobic Binding Pocket of Hsp90.
Shin SC; El-Damasy AK; Lee JH; Seo SH; Kim JH; Seo YH; Lee Y; Yu JH; Bang EK; Kim EE; Keum G
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33317068
[TBL] [Abstract][Full Text] [Related]
30. Discovery and Validation of Nitroxoline as a Novel STAT3 Inhibitor in Drug-resistant Urothelial Bladder Cancer.
Lin W; Sun J; Sadahira T; Xu N; Wada K; Liu C; Araki M; Xu A; Watanabe M; Nasu Y; Huang P
Int J Biol Sci; 2021; 17(12):3255-3267. PubMed ID: 34421363
[TBL] [Abstract][Full Text] [Related]
31. AT-533, a novel Hsp90 inhibitor, inhibits breast cancer growth and HIF-1α/VEGF/VEGFR-2-mediated angiogenesis in vitro and in vivo.
Zhang PC; Liu X; Li MM; Ma YY; Sun HT; Tian XY; Wang Y; Liu M; Fu LS; Wang YF; Chen HY; Liu Z
Biochem Pharmacol; 2020 Feb; 172():113771. PubMed ID: 31863779
[TBL] [Abstract][Full Text] [Related]
32. Debio-0932, a second generation oral Hsp90 inhibitor, induces apoptosis in MCF-7 and MDA-MB-231 cell lines.
Özgür A; Kara A; Gökşen Tosun N; Tekin Ş; Gökçe İ
Mol Biol Rep; 2021 Apr; 48(4):3439-3449. PubMed ID: 33999319
[TBL] [Abstract][Full Text] [Related]
33. KU675, a Concomitant Heat-Shock Protein Inhibitor of Hsp90 and Hsc70 that Manifests Isoform Selectivity for Hsp90α in Prostate Cancer Cells.
Liu W; Vielhauer GA; Holzbeierlein JM; Zhao H; Ghosh S; Brown D; Lee E; Blagg BS
Mol Pharmacol; 2015 Jul; 88(1):121-30. PubMed ID: 25939977
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of autophagy enhances the anticancer effect of enzalutamide on bladder cancer.
Quan Y; Lei H; Wahafu W; Liu Y; Ping H; Zhang X
Biomed Pharmacother; 2019 Dec; 120():109490. PubMed ID: 31574376
[TBL] [Abstract][Full Text] [Related]
35. Low-dose Hsp90 inhibitors tumor-selectively sensitize bladder cancer cells to chemoradiotherapy.
Yoshida S; Koga F; Tatokoro M; Kawakami S; Fujii Y; Kumagai J; Neckers L; Kihara K
Cell Cycle; 2011 Dec; 10(24):4291-9. PubMed ID: 22134243
[TBL] [Abstract][Full Text] [Related]
36. Development of a novel Hsp90 inhibitor NCT-50 as a potential anticancer agent for the treatment of non-small cell lung cancer.
Hyun SY; Le HT; Nguyen CT; Yong YS; Boo HJ; Lee HJ; Lee JS; Min HY; Ann J; Chen J; Park HJ; Lee J; Lee HY
Sci Rep; 2018 Sep; 8(1):13924. PubMed ID: 30224681
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-dependent regulation of PTEN after arsenic trioxide treatment in bladder cancer cell line T24.
Cao Y; Yu SL; Wang Y; Guo GY; Ding Q; An RH
Tumour Biol; 2011 Feb; 32(1):179-88. PubMed ID: 20857258
[TBL] [Abstract][Full Text] [Related]
38. [Influence of crocin on gene expression profile of human bladder cancer cell lines T24].
Lv CF; Luo CL; Ji HY; Zhao P
Zhongguo Zhong Yao Za Zhi; 2008 Jul; 33(13):1612-7. PubMed ID: 18837328
[TBL] [Abstract][Full Text] [Related]
39. A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation.
Chan KC; Ting CM; Chan PS; Lo MC; Lo KW; Curry JE; Smyth T; Lee AW; Ng WT; Tsao GS; Wong RN; Lung ML; Mak NK
Mol Cancer; 2013 Oct; 12(1):128. PubMed ID: 24156782
[TBL] [Abstract][Full Text] [Related]
40. Expression and Functions of Formyl Peptide Receptor 1 in Drug-Resistant Bladder Cancer.
Jiang X; Lei T; Zhang M
Technol Cancer Res Treat; 2018 Jan; 17():1533034618769413. PubMed ID: 29665744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]